enGene Cuts 50% of Staff, Overhauls Leadership, Halts Trial Cohorts

enGene Therapeutics announced a major strategic restructuring including a 50% workforce reduction to preserve cash and streamline operations. The company is pivoting its focus toward its lead program, detalimogene, following interim Phase 2 LEGEND data that showed a 54% complete response rate in BCG-unresponsive NMIBC. As part of this shift, enGene has stopped enrollment in LEGEND Cohorts 2a, 2b, and 3 to conserve capital. The restructuring will result in an estimated $5.7 to $6.4 million in cash charges and $4.7 to $5.0 million in non-cash expenses. The company also announced significant leadership changes: Chief Medical Officer Dr. Hussein Sweiti resigned, with Dr. William Grossman stepping in as interim CMO. CFO Ryan Daws, CLO Lee Giguere, and CSO Alex Nichols are also departing. Kathleen Richton will succeed Mr. Daws as Principal Financial Officer. Despite the cuts, enGene remains well-capitalized with $285.2 million in cash as of April 30, 2026. The company remains on track to engage with the FDA in 2H 2026 regarding 12-month durability data and a planned BLA initiation for detalimogene.